An update from Valneva ( (VALN) ) is now available.
On March 3, 2025, Valneva SE announced its participation in upcoming investor conferences in the United States and Europe, where senior management will present the company’s pipeline of potential first-in-class vaccine candidates, including its lead Lyme disease vaccine, VLA15. The presentations aim to highlight Valneva’s expected revenue of €170-180 million in 2025 from its portfolio of marketed vaccines. This participation reflects Valneva’s strategic efforts to engage with institutional investors and strengthen its position in the vaccine industry.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs. The company focuses on providing either first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing vaccines from early R&D to approvals. Valneva markets three proprietary travel vaccines, including the world’s first chikungunya vaccine, and is working on vaccine candidates for Lyme disease, Shigella, and Zika virus.
YTD Price Performance: 43.01%
Average Trading Volume: 64,723
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $558.8M
See more insights into VALN stock on TipRanks’ Stock Analysis page.